Rocket Pharmaceuticals

RCKT

Market cap $376M

RCKT Hedge Fund Activity: Q1 2026 in Review

198 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2026, worth a combined $348M — up 7.7% from $323M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RCKT positions and 32 closed out — a net gain of 15 holders — while 80 added to existing stakes and 53 trimmed.

The largest buyer was Marshall Wace, adding an estimated $12M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $10.5M sold.

• 198 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2026, up from 186 in Q4 2025.
• Funds reported $348M of Rocket Pharmaceuticals stock for Q1 2026, up 7.7% quarter-over-quarter.
• 47 funds opened new Rocket Pharmaceuticals positions in Q1 2026 and 32 closed out, a net change of +15 holders.
• The largest Rocket Pharmaceuticals buyer in Q1 2026 was Marshall Wace, an estimated $12M added.
• The largest Rocket Pharmaceuticals seller in Q1 2026 was Suvretta Capital Management, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2026.